Transaction #27091 · Form 4 · 0001790340-26-000004
Immuneering Corp · Stock award · Stock Option
Immuneering Corp · Transacted January 1, 2026 · Filed January 2, 2026
What does this filing report?
An SEC Form 4 filing for Immuneering Corp records a stock award involving Stock Option on January 1, 2026. The reported quantity was 7,888. The filing date is January 2, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Immuneering Corp
- Company CIK
- 0001790340
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 7,888
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 7,888
- Ownership description
- Not reported
- SEC acceptance time
- Jan 2, 2026, 4:56 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- KEATING LAURIE ↗
Director
CIK 0001620743
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Class A Common Stock
- Underlying quantity
- 7,888
- Conversion / exercise price
- 6.58
- Exercise date
- Not reported
- Expiration date
- January 1, 2036
Filing footnotes & remarks
- F1
- Pursuant to the Immuneering Corporation Non-Employee Director Compensation Program (the "Compensation Program"), the reporting person elected to receive this stock option in lieu of receiving the cash Base Retainer (as defined in the Compensation Program).
- F2
- The option vests and becomes exercisable as to 25% of the shares subject to the option upon the reporting person completing three months of continuous service as a Non-Employee Director (as defined in the Compensation Program) following the grant date, such that the fourth and final installment will vest and become exercisable on the first anniversary of the grant date, subject in each case to such continuous service.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.